Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 results that exceeded expectations, driven by accelerating demand for its Alzheimer's treatment ZUNVEYL. The company's net product revenue increased 71% quarter-over-quarter to $6.0 million, with bottles dispensed rising 37% to 8,294. June was the strongest month since launch, with 2,997 bottles dispensed, and management indicated that growth continued into the third quarter.
These results are particularly notable given that they were achieved without material stocking benefits or additional formulary wins. Downstream pharmacy benefit manager (PBM) implementation remained unchanged at approximately 16%, suggesting that the quarter's performance was driven primarily by underlying demand and improved commercial execution. This indicates a healthy foundation for future growth as payer access expands.
The breadth of adoption is widening, with 1,347 quarterly prescribers, 1,024 repeat prescribers, and 1,908 cumulative writers. Additionally, 1,095 long-term care (LTC) facilities generated prescriptions during the quarter. This growing prescriber and facility productivity provides a meaningful growth path even before broader payer activation. As more PBMs implement coverage, the potential for additional revenue is substantial.
Alpha Cognition is balancing its commercial investment with a growing evidence base. The company lowered its full-year 2026 research and development (R&D) and selling, general, and administrative (SG&A) guidance to $50 million to $54 million, while maintaining its target of operating profitability by 2027. This disciplined approach to spending, combined with revenue growth, positions the company for improved operating leverage.
Several key milestones are on the horizon. The CONVERGE data are expected in the third quarter of 2026, and the RESOLVE study is underway. The sublingual program is gated by comparative pharmacokinetic (PK) results. These developments could provide additional catalysts for the company as it works toward greater financial efficiency.
Investors and industry observers are watching Alpha Cognition closely. The company's ability to grow demand despite limited payer coverage underscores the potential of ZUNVEYL. As payer implementation gradually increases, the company could see a significant acceleration in sales. The upcoming data readouts and continued commercial execution will be critical to watch.
Stonegate Capital Partners, which provides coverage on Alpha Cognition, highlighted that the second-quarter results strengthen the ZUNVEYL launch setup. The combination of breadth (more prescribers and facilities), depth (repeat utilization), and the potential for payer upside creates a compelling narrative. While the current access backdrop is not fully reflective of the product's potential, the underlying demand signals are strong.
For more details on the full announcement, including downloadable images and bios, please visit Stonegate Capital Partners.
